198 related articles for article (PubMed ID: 29363546)
21. The development of a model for the homing of multiple myeloma cells to human bone marrow.
Urashima M; Chen BP; Chen S; Pinkus GS; Bronson RT; Dedera DA; Hoshi Y; Teoh G; Ogata A; Treon SP; Chauhan D; Anderson KC
Blood; 1997 Jul; 90(2):754-65. PubMed ID: 9226176
[TBL] [Abstract][Full Text] [Related]
22. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation.
Dabbah M; Attar-Schneider O; Zismanov V; Tartakover Matalon S; Lishner M; Drucker L
J Leukoc Biol; 2016 Oct; 100(4):761-770. PubMed ID: 27272311
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of insulin-like growth factor 1 exerts a protective effect on hypoxic injury of aged BM-MSCs: role of autophagy.
Yang M; Wen T; Chen H; Deng J; Yang C; Zhang Z
Stem Cell Res Ther; 2018 Oct; 9(1):284. PubMed ID: 30359321
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells.
Feng Y; Wen J; Mike P; Choi DS; Eshoa C; Shi ZZ; Zu Y; Chang CC
Stem Cells Dev; 2010 Sep; 19(9):1289-96. PubMed ID: 20121456
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
[TBL] [Abstract][Full Text] [Related]
26. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
27. Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.
De Bruyne E; Andersen TL; De Raeve H; Van Valckenborgh E; Caers J; Van Camp B; Delaissé JM; Van Riet I; Vanderkerken K
Leukemia; 2006 Oct; 20(10):1870-9. PubMed ID: 16900214
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
Martin SK; Diamond P; Williams SA; To LB; Peet DJ; Fujii N; Gronthos S; Harris AL; Zannettino AC
Haematologica; 2010 May; 95(5):776-84. PubMed ID: 20015878
[TBL] [Abstract][Full Text] [Related]
29. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.
Zheng Y; Yang J; Qian J; Qiu P; Hanabuchi S; Lu Y; Wang Z; Liu Z; Li H; He J; Lin P; Weber D; Davis RE; Kwak L; Cai Z; Yi Q
Leukemia; 2013 Mar; 27(3):702-10. PubMed ID: 22996336
[TBL] [Abstract][Full Text] [Related]
30. Vav proteins are required for B-lymphocyte responses to LPS.
Hebeis B; Vigorito E; Kovesdi D; Turner M
Blood; 2005 Jul; 106(2):635-40. PubMed ID: 15811961
[TBL] [Abstract][Full Text] [Related]
31. Correlation of the expression of CD32 and CD180 receptors on CLL cells and MEC1 cell line.
Tsertsvadze T; Mitskevich N; Ghirdaladze D; Porakishvili N
Georgian Med News; 2015 Mar; (240):56-9. PubMed ID: 25879560
[TBL] [Abstract][Full Text] [Related]
32. Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant.
Okamoto M; Oh-E G; Oshikawa T; Furuichi S; Tano T; Ahmed SU; Akashi S; Miyake K; Takeuchi O; Akira S; Himeno K; Sato M; Ohkubo S
Clin Diagn Lab Immunol; 2004 May; 11(3):483-95. PubMed ID: 15138173
[TBL] [Abstract][Full Text] [Related]
33. The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
Storti P; Toscani D; Airoldi I; Marchica V; Maiga S; Bolzoni M; Fiorini E; Campanini N; Martella E; Mancini C; Guasco D; Ferri V; Donofrio G; Aversa F; Amiot M; Giuliani N
Haematologica; 2016 Mar; 101(3):e107-10. PubMed ID: 26659917
[No Abstract] [Full Text] [Related]
34. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
36. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
[TBL] [Abstract][Full Text] [Related]
37. Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.
Li Y; Zheng Y; Li T; Wang Q; Qian J; Lu Y; Zhang M; Bi E; Yang M; Reu F; Yi Q; Cai Z
Oncotarget; 2015 Sep; 6(27):24218-29. PubMed ID: 26155942
[TBL] [Abstract][Full Text] [Related]
38. Transforming growth factor β induces bone marrow mesenchymal stem cell migration via noncanonical signals and N-cadherin.
Dubon MJ; Yu J; Choi S; Park KS
J Cell Physiol; 2018 Jan; 233(1):201-213. PubMed ID: 28213973
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.
Tsukamoto S; Løvendorf MB; Park J; Salem KZ; Reagan MR; Manier S; Zavidij O; Rahmat M; Huynh D; Takagi S; Kawano Y; Kokubun K; Thrue CA; Nagano K; Petri A; Roccaro AM; Capelletti M; Baron R; Kauppinen S; Ghobrial IM
Leukemia; 2018 Aug; 32(8):1739-1750. PubMed ID: 29925904
[TBL] [Abstract][Full Text] [Related]
40. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
